Compound | Target | Combined agent | Rationale | Cancer type | Status | Reference |
---|---|---|---|---|---|---|
Romidepsin | HDAC | NA | Inhibition of histone deacetylation | Relapsed SCLC | Clinical trial (NCT00086827), phase II, completed | 14 |
Pracinostat | HDAC | NA | Inhibition of histone deacetylation | Crebbp-deleted SCLC | Mouse in vivo treatment | 15 |
Panobinostat/LBH589 | HDAC | NA | Inhibition of histone deacetylation | SCLC | Clinical trial (NCT01222936), phase II | 16 |
GSK2879552 | LSD1/KDM1A | NA | Inhibition of H3K4 and H3K9 demethylation | SCLC | Cell line in vitro treatment and PDX in vivo treatment | 5 |
GSK2879552 | LSD1/KDM1A | NA | Inhibition of H3K4 and H3K9 demethylation | Relapsed/refractory SCLC | Clinical trial (NCT02034123), phase I, terminated | 17 |
Olaparib | PARP | Temozolomide | Inhibitor of poly(ADP-ribose) polymerase | Relapsed SCLC | Clinical trial (NCT 02446704), phase I and phase II, active, not recruiting | 18 |
Veliparib | PARP | Temozolomide | Inhibitor of poly(ADP-ribose) polymerase | Relapsed-sensitive or refractory SCLC | Clinical trial (NCT01638546), phase II, completed | 19 |
Veliparib | PARP | E/P | Inhibitor of poly(ADP-ribose) polymerase | Extensive-stage SCLC | Clinical trial (NCT01642251), phase II, completed | 20 |
EPZ011989 | EZH2 | E/P | Inhibition of H3K27me3 | Both chemosensitive and chemoresistant models of SCLC | PDX in vivo treatment | 10 |
SAM | NA | NA | Increase in DNA 5-methylcytosine, H3K4me1, and H3K4me2 levels | SCLC | Mouse in vivo treatment and patient sample in vitro treatment | 2 |
PDX, patient-derived xenograft; NA, not available.